Targeted diagnosis and therapy最新文献_第6页

The Aspergillus ribonucleolytic toxins (ribotoxins). 曲霉的核糖溶核毒素(核素毒素)。

Targeted diagnosis and therapy Pub Date : 1992-01-01

B Lamy, J Davies, D Schindler

引用次数: 0

An efficient expression system for alpha-sarcin in Escherichia coli. α -肌氨酸在大肠杆菌中的高效表达体系。

Targeted diagnosis and therapy Pub Date : 1992-01-01

Y Endo, T Oka, Y Aoyama

引用次数: 0

Generation of chimeric toxins. 产生嵌合毒素。

Targeted diagnosis and therapy Pub Date : 1992-01-01 DOI: 10.1201/9781003066651-24

D. Fitzgerald, V. Chaudhary, R. Kreitman, C. Siegall, I. Pastan

引用次数: 2

Genetically engineered toxins in perspective. 正确看待基因工程毒素。

Targeted diagnosis and therapy Pub Date : 1992-01-01 DOI: 10.1201/9781003066651-25

S. Olsnes, A. Frankel

引用次数: 0

Imaging of colorectal carcinoma with 131I B72.3 monoclonal antibody. 131I B72.3单克隆抗体在结直肠癌中的显像。

Targeted diagnosis and therapy Pub Date : 1992-01-01

J A Carrasquillo

引用次数: 0

Multicenter clinical trials of monoclonal antibody B72.3-GYK-DTPA 111In (111In-CYT-103; OncoScint CR103) in patients with colorectal carcinoma. B72.3-GYK-DTPA 111In (111In- cyt -103;OncoScint CR103)在结直肠癌患者中的应用。

Targeted diagnosis and therapy Pub Date : 1992-01-01

H H Abdel-Nabi, R J Doerr

{"title":"Multicenter clinical trials of monoclonal antibody B72.3-GYK-DTPA 111In (111In-CYT-103; OncoScint CR103) in patients with colorectal carcinoma.","authors":"H H Abdel-Nabi, R J Doerr","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The results of this clinical trial involving 23 sites indicated that 111In-CYT-103 immunoscintigraphy identified 70% of all patients with surgically confirmed disease when interpreted by the on-site physician. The sensitivity of 111In-CYT-103 imaging was slightly lower when interpreted retrospectively by the blinded readers in the absence of any patient-specific information. 111In-CYT-103 imaging sensitivity was similar in patients with primary and recurrent disease, but lower for liver metastases than for extrahepatic disease. Thirty-three previously unknown lesions were visualized by immunoscintigraphy; tissue confirmation was available for only five lesions, and all were found to be free of tumor. Only one of the lesions evaluated was TAG-72 positive. Twenty-eight lesions were outside the surgical field or not biopsied. Although no tissue confirmation was available, seven (25%) of these lesions were identified as consistent with metastatic disease by other conventional modalities. Importantly, antibody scans detected occult tumor lesions in 11 of the 92 patients with surgically confirmed adenocarcinoma, and accurately diagnosed 7 of 10 patients with elevated serum CEA levels and negative conventional workup. Surgery confirmed the presence of tumor identified only by 111In-CYT-103 in three patients, while four patients with negative scans had no evidence of recurrent disease at surgery. Antibody scans confirmed the absence of additional disease in 18 of 22 patients with isolated hepatic or pelvic recurrences in whom curative surgery was contemplated. The results of this multicenter trial suggest that CYT-103 immunoscintigraphy can provide information that is complementary to that derived from standard diagnostic techniques. During the workup of patients with primary colorectal carcinoma, this modality assesses the entire body and allows for the identification of multiple lesions at various locations simultaneously. It can then redirect attention and further workup to those areas not originally surveyed. Of special interest in this regard is the identification of occult lesions in five patients with primary colorectal cancer. 111In-CYT-103 imaging was found superior to CT in the localization of primary colorectal cancer, but neither modality could adequately assess the extent of tumor penetration through the bowel wall (the T stage in the TNM system) or the N status. The limitations of CT in evaluating T and N are well documented, and the limitations of 111In-based immunoscintigraphy for these same lesions have recently been described. Another limitation of 111In-CYT-103 immunoscintigraphy is in the identification of liver metastases.(ABSTRACT TRUNCATED AT 400 WORDS)</p>","PeriodicalId":77632,"journal":{"name":"Targeted diagnosis and therapy","volume":"6 ","pages":"73-88"},"PeriodicalIF":0.0,"publicationDate":"1992-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12743617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Genetically engineered toxins in perspective. 正确看待基因工程毒素。

Targeted diagnosis and therapy Pub Date : 1992-01-01

S Olsnes, A E Frankel

引用次数: 0

Genetically engineered toxins. General methods. 基因工程毒素。通用的方法。

Targeted diagnosis and therapy Pub Date : 1992-01-01

R F Weaver

引用次数: 0

Protein engineering of diphtheria toxin. Development of receptor-specific cytotoxic agents for the treatment of human disease. 白喉毒素蛋白工程。用于治疗人类疾病的受体特异性细胞毒性药物的开发。

Targeted diagnosis and therapy Pub Date : 1992-01-01 DOI: 10.1201/9781003066651-18

J. Murphy, Fadi G Lakkis, J. vanderSpek, P. Anderson, T. Strom